<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761266</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-G000-304</org_study_id>
    <secondary_id>2012-002992-33</secondary_id>
    <nct_id>NCT01761266</nct_id>
  </id_info>
  <brief_title>A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to
      compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic
      treatment in participants with unresectable Hepatocellular Carcinoma (HCC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2013</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">November 13, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of randomization until date of death from any cause (approximately up to 3.8 years)</time_frame>
    <description>OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
    <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)</time_frame>
    <description>TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
    <description>ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>Baseline up to Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
    <description>The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)</measure>
    <time_frame>Baseline up to Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
    <description>The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = &quot;not at all&quot; and 4 = &quot;very much.&quot; All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)</measure>
    <time_frame>Baseline up to Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
    <description>The EuroQol five dimension health questionnaire (EQ-5D-3L) was a health profile questionnaire that assessed quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with &quot;3&quot; corresponding to no problems and &quot;15&quot; corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib</measure>
    <time_frame>Cycle 1 Day 1, Cycle 1 Day 2: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)</time_frame>
    <description>AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 2 and Cycle 1 Day 15. Summarized data for all time points was reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
    <description>DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been &gt;=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
    <description>CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD &gt;=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change From Baseline in Serum Biomarker</measure>
    <time_frame>Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
    <description>The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">954</enrollment>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Lenvatinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (&gt;=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (&lt;) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>12 mg (or 8 mg) once daily (QD) oral dosing.</description>
    <arm_group_label>Lenvatinib</arm_group_label>
    <other_name>E7080, Lenvima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg twice daily (BID) oral dosing.</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Participants must have confirmed diagnosis of unresectable HCC with any of the
             following criteria:

               -  Histologically or cytologically confirmed diagnosis of HCC.

               -  Clinically confirmed diagnosis of HCC according to American Association for the
                  Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or
                  with chronic hepatitis B or C infection criteria

          2. At least one measurable target lesion according to modified Response Evaluation
             Criteria in Solid Tumors (mRECIST) meeting the following criteria:

             • Hepatic lesion

               1. The lesion can be accurately measured in at least one dimension as &gt;=1.0
                  centimeter (cm) (viable tumor for typical; and longest diameter for atypical),
                  and

               2. The lesion is suitable for repeat measurement.

                  • Nonhepatic lesion

               3. Lymph node (LN) lesion that measures at least one dimension as &gt;=1.5 cm in the
                  short axis, except for porta hepatis LN that measures &gt;=2.0 cm in the short axis.

               4. Non-nodal lesion that measures &gt;=1.0 cm in the longest diameter Lesions
                  previously treated with radiotherapy or locoregional therapy must show
                  radiographic evidence of disease progression to be deemed a target lesion.

          3. Participants categorized to stage B (not applicable for transarterial
             chemoembolization [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC)
             staging system.

          4. Adequate bone marrow function, defined as:

               -  Absolute neutrophil count (ANC) &gt;=1.5 X 10^9 per liter (/L)

               -  Hemoglobin (Hb) &gt;=8.5 gram per deciliter (g/dL)

               -  Platelet count &gt;=75 X 10^9/L.

          5. Adequate liver function, defined as:

               -  Albumin &gt;=2.8 g/dL

               -  Bilirubin less than or equal to (&lt;=) 3.0 mg/dL

               -  Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine
                  aminotransferase (ALT) &lt;=5 X the upper limit of normal (ULN).

          6. Adequate blood coagulation function, defined as international normalized ratio (INR)
             &lt;=2.3.

          7. Adequate renal function defined as creatinine clearance greater than (&gt;) 40 milliliter
             per minute (mL/min) calculated per the Cockcroft and Gault formula.

          8. Adequate pancreatic function, defined as amylase and lipase &lt;=1.5 X ULN.

          9. Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents,
             defined as BP &lt;=150/90 millimeters of mercury (mmHg) at Screening and no change in
             antihypertensive therapy within 1 week prior to the Cycle1/Day1.

         10. Child-Pugh score A.

         11. Eastern Cooperative Oncology Group (ECOG)- performance status (PS) 0 or 1.

         12. Males or females aged at least 18 years (or any age &gt;18 years as determined by country
             legislation) at the time of informed consent.

         13. Females must not be lactating or pregnant at Screening or Baseline (as documented by a
             negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of
             25 International Units Per Liter (IU/L) or equivalent units of BhCG).

             A separate baseline assessment is required if a negative screening pregnancy test was
             obtained more than 72 hours before the first dose of study drug.

         14. All females will be considered to be of childbearing potential unless they are
             postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age
             group and without other known or suspected cause) or have been sterilized surgically
             (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with
             surgery at least 1 month before dosing).

         15. Females of childbearing potential must not have had unprotected sexual intercourse
             within 30 days before study entry and must agree to use a highly effective method of
             contraception (e.g., total abstinence, an intrauterine device, a double barrier method
             [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral
             contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout
             the entire study period and for 30 days after study drug discontinuation. If currently
             abstinent, the participant must agree to use a double barrier method as described
             above if she becomes sexually active during the study period or for 30 days after
             study drug discontinuation. Females who are using hormonal contraceptives must have
             been on a stable dose of the same hormonal contraceptive product for at least 4 weeks
             before dosing and must continue to use the same contraceptive during the study and for
             30 days after study drug discontinuation.

         16. Male participants must have had a successful vasectomy (confirmed azoospermia) or they
             and their female partners must meet the criteria above (i.e., not of childbearing
             potential or practicing highly effective contraception throughout the study period and
             for 30 days after study drug discontinuation). No sperm donation is allowed during the
             study period and for 30 days after study drug discontinuation.

         17. Provide written informed consent.

         18. Willing and able to comply with all aspects of the protocol.

        Exclusion Criteria

          1. Imaging findings for HCC corresponding to any of the following:

               -  HCC with &gt;=50 percent liver occupation

               -  Clear invasion into the bile duct

               -  Portal vein invasion at the main portal branch (Vp4).

          2. Participants who have received any systemic chemotherapy, including anti-vascular
             endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer
             agents, including lenvatinib, for advanced/unresectable HCC. Note: Participants who
             have received local hepatic injection chemotherapy are eligible.

          3. Participants who have received any anticancer therapy (including surgery, percutaneous
             ethanol injection, radio frequency ablation, transarterial [chemo] embolization,
             hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or
             radiotherapy) or any blood enhancing treatment (including blood transfusion, blood
             products, or agents that stimulate blood cell production, eg, granulocyte
             colony-stimulating factor [G-CSF]) within 28 days prior to randomization.

          4. Participants who have not recovered from toxicities as a result of prior anticancer
             therapy, except alopecia and infertility. Recovery is defined as &lt; Grade 2 severity
             per Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).

          5. Significant cardiovascular impairment: history of congestive heart failure &gt; New York
             Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke
             within 6 months of the first dose of study drug, or cardiac arrhythmia requiring
             medical treatment at Screening.

          6. Prolongation of corrected QT interval (QTc) interval to &gt;480 millisecond (ms)

          7. Gastrointestinal malabsorption or any other condition that might affect the absorption
             of lenvatinib in the opinion of the investigator.

          8. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR
             monitoring, eg, warfarin or similar agents. Treatment with low molecular weight
             heparin and factor X inhibitors which do not require INR monitoring is permitted.
             Antiplatelet agents are prohibited throughout the study.

          9. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5
             teaspoon) within 28 days prior to randomization.

         10. Gastric or esophageal varices that require interventional treatment within 28 days
             prior to randomization. Prophylaxis with pharmacologic therapy (eg, nonselective
             beta-blocker) is permitted.

         11. Active malignancy (except for HCC or definitively treated melanoma in-situ, basal or
             squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the
             past 36 months.

         12. Participants whose only target lesion(s) is in bone will be excluded.

         13. Meningeal carcinomatosis.

         14. Any history of or current brain or subdural metastases.

         15. Participants having &gt;1+ proteinuria on urine dipstick testing will undergo a 24-hour
             urine collection for quantitative assessment of proteinuria. Participants with a urine
             protein &gt;=1g/24 hours will be ineligible.

         16. Surgical arterial-portal venous shunt or arterial-venous shunt.

         17. Any medical or other condition that in the opinion of the investigator would preclude
             the participant's participation in a clinical study.

         18. Known intolerance to lenvatinib or sorafenib (or any of the excipients).

         19. Human immunodeficiency virus (HIV) positive or active infection requiring treatment
             (except for hepatitis virus).

         20. Any history of drug or alcohol dependency or abuse within the prior 6 months.

         21. Any participant who cannot be evaluated by either triphasic liver computed tomography
             (CT) or triphasic liver Magnetic resonance imaging (MRI) because of allergy or other
             contraindication to both CT and MRI contrast agents.

         22. Major surgery within 3 weeks prior to randomization or scheduled for surgery during
             the study.

         23. Participants has had a liver transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Wentworthville</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Tianjin</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Nice Cedex 3</city>
        <state>Alpes Maritimes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Pessac Cedex</city>
        <state>Gironde</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Pessac</city>
        <state>Gironde</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Rennes cedex</city>
        <state>Ille Et Vilaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe Et Moselle</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Amiens cedex 1</city>
        <state>Somme</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Creteil Cedex</city>
        <state>Val De Marne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Lille cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Nord</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Rhone</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland Pfalz</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Petah Tiqwa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Torrette</city>
        <state>Ancona</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Osaka-Sayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Bunkyo-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Seongnam-Si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Seongnam-Si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 4</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 5</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 6</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 7</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 8</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kuantan</city>
        <state>Pahang</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Penang</city>
        <state>Pulau Pinang</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Miri</city>
        <state>Sarawak</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor</state>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 4</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 4</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 4</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 4</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 5</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Taoyuan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Pathum Wan</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Muang</city>
        <state>Chiang Rai</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 2</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 3</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facility # 1</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 2, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <results_first_submitted>August 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2018</results_first_posted>
  <disposition_first_submitted>January 18, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 19, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 25, 2018</disposition_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 154 investigative sites in Australia, Belgium, Canada, China, France, Germany, HongKong, Israel, Italy, Japan,SouthKorea, Malaysia,Philippines,Poland,Russia,Singapore,Spain,Taiwan,Thailand,United Kingdom and the United States from 1 March 2013 to 13 November 2016 (date of data cutoff for the primary analysis).</recruitment_details>
      <pre_assignment_details>A total of 1,492 participants were screened, 954 participants were enrolled and randomized, out of which 951 participants were treated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenvatinib</title>
          <description>Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (&gt;=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (&lt;) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
        </group>
        <group group_id="P2">
          <title>Sorafenib</title>
          <description>Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="478"/>
                <participants group_id="P2" count="476"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="476"/>
                <participants group_id="P2" count="475"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="478"/>
                <participants group_id="P2" count="476"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="351"/>
                <participants group_id="P2" count="350"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing as of data-cut off</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set (FAS) included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Lenvatinib</title>
          <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
        </group>
        <group group_id="B2">
          <title>Sorafenib</title>
          <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="478"/>
            <count group_id="B2" value="476"/>
            <count group_id="B3" value="954"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="11.69"/>
                    <measurement group_id="B2" value="61.2" spread="12.01"/>
                    <measurement group_id="B3" value="61.3" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="472"/>
                    <measurement group_id="B2" value="465"/>
                    <measurement group_id="B3" value="937"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="326"/>
                    <measurement group_id="B3" value="660"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="276"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.</description>
        <time_frame>From date of randomization until date of death from any cause (approximately up to 3.8 years)</time_frame>
        <population>The full analysis set (FAS) included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.</description>
          <population>The full analysis set (FAS) included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" lower_limit="12.1" upper_limit="14.9"/>
                    <measurement group_id="O2" value="12.3" lower_limit="10.4" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
        <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="6.9" upper_limit="8.8"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP)</title>
        <description>TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
        <time_frame>The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="7.4" upper_limit="9.2"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions.</description>
        <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="20.2" upper_limit="27.9"/>
                    <measurement group_id="O2" value="9.2" lower_limit="6.6" upper_limit="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</title>
        <description>The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.</description>
        <time_frame>Baseline up to Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</title>
          <description>The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.05" upper_limit="1.84"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.05" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)</title>
        <description>The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = &quot;not at all&quot; and 4 = &quot;very much.&quot; All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem.</description>
        <time_frame>Baseline up to Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)</title>
          <description>The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = &quot;not at all&quot; and 4 = &quot;very much.&quot; All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.81" upper_limit="1.97"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.74" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaundice</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.72" upper_limit="5.52"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.86" upper_limit="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Image</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.73" upper_limit="3.68"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.84" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nutrition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.68" upper_limit="5.52"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.04" upper_limit="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.97" upper_limit="2.83"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.73" upper_limit="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.57" upper_limit="6.51"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.99" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="5.46" upper_limit="9.17"/>
                    <measurement group_id="O2" value="6.7" lower_limit="4.60" upper_limit="13.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="5.52" upper_limit="9.24"/>
                    <measurement group_id="O2" value="7.4" lower_limit="5.46" upper_limit="10.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)</title>
        <description>The EuroQol five dimension health questionnaire (EQ-5D-3L) was a health profile questionnaire that assessed quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with &quot;3&quot; corresponding to no problems and &quot;15&quot; corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death.</description>
        <time_frame>Baseline up to Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)</title>
          <description>The EuroQol five dimension health questionnaire (EQ-5D-3L) was a health profile questionnaire that assessed quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with &quot;3&quot; corresponding to no problems and &quot;15&quot; corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.17" upper_limit="3.65"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.84" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.97" upper_limit="3.52"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.84" upper_limit="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib</title>
        <description>AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 2 and Cycle 1 Day 15. Summarized data for all time points was reported.</description>
        <time_frame>Cycle 1 Day 1, Cycle 1 Day 2: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)</time_frame>
        <population>The pharmacokinetic (PK) analysis set included all participants who had received at least 1 dose of lenvatinib and had at least 1 quantifiable lenvatinib concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib 8 mg</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Lenvatinib 12 mg</title>
            <description>Participants received lenvatinib 12 mg capsules based on the participant's body weight (&gt;=60 kg) at Baseline, orally, once daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib</title>
          <description>AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 2 and Cycle 1 Day 15. Summarized data for all time points was reported.</description>
          <population>The pharmacokinetic (PK) analysis set included all participants who had received at least 1 dose of lenvatinib and had at least 1 quantifiable lenvatinib concentration.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1969.6" spread="743.0"/>
                    <measurement group_id="O2" value="2120.9" spread="685.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Disease Control Rate (DCR)</title>
        <description>DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been &gt;=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
        <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been &gt;=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="71.7" upper_limit="79.4"/>
                    <measurement group_id="O2" value="60.5" lower_limit="56.1" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Benefit Rate (CBR)</title>
        <description>CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD &gt;=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
        <time_frame>From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)</time_frame>
        <population>The FAS included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR)</title>
          <description>CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD &gt;=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.</description>
          <population>The FAS included all participants who were randomized.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="476"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" lower_limit="54.6" upper_limit="63.4"/>
                    <measurement group_id="O2" value="38.4" lower_limit="34.1" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent Change From Baseline in Serum Biomarker</title>
        <description>The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum.</description>
        <time_frame>Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)</time_frame>
        <population>The pharmacodynamics (PD) analysis set included all participants who received at least 1 dose of study drug and had evaluable PD data. Here “n” was participants who were evaluable for the outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenvatinib</title>
            <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;= 60 kg or 8 mg based on the participant's body weight &lt; 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Sorafenib</title>
            <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Biomarker</title>
          <description>The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum.</description>
          <population>The pharmacodynamics (PD) analysis set included all participants who received at least 1 dose of study drug and had evaluable PD data. Here “n” was participants who were evaluable for the outcome measure at given time points.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANG 2: Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="15.94"/>
                    <measurement group_id="O2" value="8.9" spread="23.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.8" spread="16.53"/>
                    <measurement group_id="O2" value="-0.9" spread="24.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.2" spread="23.23"/>
                    <measurement group_id="O2" value="0.5" spread="26.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.6" spread="22.91"/>
                    <measurement group_id="O2" value="-4.5" spread="20.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.9" spread="19.83"/>
                    <measurement group_id="O2" value="7.0" spread="23.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.7" spread="23.59"/>
                    <measurement group_id="O2" value="-3.6" spread="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.4" spread="21.20"/>
                    <measurement group_id="O2" value="1.0" spread="32.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.2" spread="25.33"/>
                    <measurement group_id="O2" value="-6.7" spread="31.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.6" spread="14.04"/>
                    <measurement group_id="O2" value="-1.1" spread="29.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG 2: Off-Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="99.13"/>
                    <measurement group_id="O2" value="16.8" spread="27.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="155.01"/>
                    <measurement group_id="O2" value="1.3" spread="83.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" spread="134.26"/>
                    <measurement group_id="O2" value="36.6" spread="119.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" spread="123.85"/>
                    <measurement group_id="O2" value="22.8" spread="70.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.1" spread="602.11"/>
                    <measurement group_id="O2" value="46.8" spread="214.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.8" spread="228.37"/>
                    <measurement group_id="O2" value="-1.0" spread="40.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.8" spread="203.81"/>
                    <measurement group_id="O2" value="26.9" spread="67.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" spread="101.97"/>
                    <measurement group_id="O2" value="-5.9" spread="57.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" spread="135.31"/>
                    <measurement group_id="O2" value="53.9" spread="113.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.3" spread="202.00"/>
                    <measurement group_id="O2" value="56.6" spread="109.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF19: Off-Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.1" spread="270.73"/>
                    <measurement group_id="O2" value="9.0" spread="64.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="75.22"/>
                    <measurement group_id="O2" value="4.0" spread="43.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="77.44"/>
                    <measurement group_id="O2" value="18.6" spread="57.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="38.3"/>
                    <measurement group_id="O2" value="49.4" spread="76.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="145.43"/>
                    <measurement group_id="O2" value="32.8" spread="70.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="95.97"/>
                    <measurement group_id="O2" value="31.1" spread="43.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" spread="168.22"/>
                    <measurement group_id="O2" value="23.2" spread="40.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" spread="128.34"/>
                    <measurement group_id="O2" value="23.7" spread="53.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21 : Cycle 8 Day1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="115.53"/>
                    <measurement group_id="O2" value="17.0" spread="68.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Cycle 9 Day1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" spread="108.39"/>
                    <measurement group_id="O2" value="68.9" spread="103.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 21: Off-Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.4" spread="340.51"/>
                    <measurement group_id="O2" value="104.9" spread="183.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 1 Day15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="49.01"/>
                    <measurement group_id="O2" value="-16.3" spread="36.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="56.91"/>
                    <measurement group_id="O2" value="-6.2" spread="48.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="45.27"/>
                    <measurement group_id="O2" value="17.3" spread="75.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="48.38"/>
                    <measurement group_id="O2" value="14.2" spread="49.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="63.69"/>
                    <measurement group_id="O2" value="1.0" spread="47.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="54.57"/>
                    <measurement group_id="O2" value="-10.6" spread="46.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="57.44"/>
                    <measurement group_id="O2" value="0.7" spread="46.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="67.35"/>
                    <measurement group_id="O2" value="2.8" spread="43.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="62.58"/>
                    <measurement group_id="O2" value="0.5" spread="38.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF 23: Off-Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="73.59"/>
                    <measurement group_id="O2" value="14.2" spread="47.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="171.41"/>
                    <measurement group_id="O2" value="166.9" spread="256.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.7" spread="329.33"/>
                    <measurement group_id="O2" value="243.8" spread="416.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.4" spread="611.40"/>
                    <measurement group_id="O2" value="218.7" spread="281.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371.7" spread="812.45"/>
                    <measurement group_id="O2" value="196.2" spread="348.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628.2" spread="1752.64"/>
                    <measurement group_id="O2" value="369.5" spread="766.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648.7" spread="2746.41"/>
                    <measurement group_id="O2" value="415.7" spread="554.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.8" spread="352.75"/>
                    <measurement group_id="O2" value="703.6" spread="1226.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277.8" spread="481.53"/>
                    <measurement group_id="O2" value="724.0" spread="1257.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="318.8" spread="577.21"/>
                    <measurement group_id="O2" value="859.1" spread="1492.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIVKA-II: Off-Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="809.3" spread="1827.42"/>
                    <measurement group_id="O2" value="272.5" spread="489.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="59"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.5" spread="300.21"/>
                    <measurement group_id="O2" value="97.4" spread="118.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.9" spread="333.85"/>
                    <measurement group_id="O2" value="94.0" spread="180.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="162.39"/>
                    <measurement group_id="O2" value="66.0" spread="124.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.4" spread="231.19"/>
                    <measurement group_id="O2" value="76.1" spread="111.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.4" spread="249.59"/>
                    <measurement group_id="O2" value="116.2" spread="215.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.1" spread="219.36"/>
                    <measurement group_id="O2" value="130.9" spread="341.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.1" spread="383.43"/>
                    <measurement group_id="O2" value="96.9" spread="173.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.7" spread="349.58"/>
                    <measurement group_id="O2" value="181.1" spread="399.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.6" spread="215.05"/>
                    <measurement group_id="O2" value="135.6" spread="267.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF: Off-Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.1" spread="266.64"/>
                    <measurement group_id="O2" value="147.8" spread="304.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All treatment-emergent adverse events were collected from first dose of study drug (Baseline) up to 30 days after last dose of study drug (approximately up to 3.8 years)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenvatinib</title>
          <description>Participants received lenvatinib capsules 12 mg based on the participant's body weight &gt;=60 kg or 8 mg based on the participant's body weight &lt;60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
        </group>
        <group group_id="E2">
          <title>Sorafenib</title>
          <description>Participants received sorafenib 400 mg tablets, orally, twice daily in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="350" subjects_at_risk="476"/>
                <counts group_id="E2" subjects_affected="350" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="476"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Heart valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="476"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="476"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="476"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="476"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="476"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemobilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Clostridium test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="476"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Liver carcinoma ruptured</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tumour necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Tumour rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="476"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Coma hepatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Paralysis recurrent laryngeal nerve</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hepatopulmonary syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Necrotising bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Non-cardiogenic pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="476"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="476"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="469" subjects_at_risk="476"/>
                <counts group_id="E2" subjects_affected="469" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="476"/>
                <counts group_id="E2" events="46" subjects_affected="42" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="44" subjects_affected="33" subjects_at_risk="476"/>
                <counts group_id="E2" events="36" subjects_affected="28" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="79" subjects_affected="78" subjects_at_risk="476"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="49" subjects_affected="38" subjects_at_risk="476"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="105" subjects_affected="79" subjects_at_risk="476"/>
                <counts group_id="E2" events="99" subjects_affected="83" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="66" subjects_affected="58" subjects_at_risk="476"/>
                <counts group_id="E2" events="48" subjects_affected="40" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="68" subjects_affected="61" subjects_at_risk="476"/>
                <counts group_id="E2" events="42" subjects_affected="37" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="89" subjects_affected="76" subjects_at_risk="476"/>
                <counts group_id="E2" events="60" subjects_affected="52" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="325" subjects_affected="183" subjects_at_risk="476"/>
                <counts group_id="E2" events="350" subjects_affected="219" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="476"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="111" subjects_affected="91" subjects_at_risk="476"/>
                <counts group_id="E2" events="77" subjects_affected="68" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="55" subjects_affected="45" subjects_at_risk="476"/>
                <counts group_id="E2" events="67" subjects_affected="56" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="102" subjects_affected="73" subjects_at_risk="476"/>
                <counts group_id="E2" events="57" subjects_affected="36" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="52" subjects_at_risk="476"/>
                <counts group_id="E2" events="54" subjects_affected="48" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="155" subjects_affected="140" subjects_at_risk="476"/>
                <counts group_id="E2" events="129" subjects_affected="118" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="83" subjects_affected="64" subjects_at_risk="476"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="63" subjects_at_risk="476"/>
                <counts group_id="E2" events="68" subjects_affected="60" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="66" subjects_affected="53" subjects_at_risk="476"/>
                <counts group_id="E2" events="66" subjects_affected="52" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="80" subjects_affected="64" subjects_at_risk="476"/>
                <counts group_id="E2" events="100" subjects_affected="80" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="32" subjects_at_risk="476"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="92" subjects_affected="66" subjects_at_risk="476"/>
                <counts group_id="E2" events="74" subjects_affected="62" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="45" subjects_affected="33" subjects_at_risk="476"/>
                <counts group_id="E2" events="47" subjects_affected="24" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="37" subjects_at_risk="476"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="69" subjects_affected="40" subjects_at_risk="476"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="117" subjects_affected="87" subjects_at_risk="476"/>
                <counts group_id="E2" events="66" subjects_affected="57" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="165" subjects_affected="147" subjects_at_risk="476"/>
                <counts group_id="E2" events="113" subjects_affected="106" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="80" subjects_affected="46" subjects_at_risk="476"/>
                <counts group_id="E2" events="37" subjects_affected="23" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="192" subjects_affected="159" subjects_at_risk="476"/>
                <counts group_id="E2" events="137" subjects_affected="125" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="43" subjects_at_risk="476"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="42" subjects_at_risk="476"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="53" subjects_affected="48" subjects_at_risk="476"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="50" subjects_affected="47" subjects_at_risk="476"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="47" subjects_affected="37" subjects_at_risk="476"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="53" subjects_affected="45" subjects_at_risk="476"/>
                <counts group_id="E2" events="40" subjects_affected="38" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="476"/>
                <counts group_id="E2" events="29" subjects_affected="27" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="162" subjects_affected="116" subjects_at_risk="476"/>
                <counts group_id="E2" events="74" subjects_affected="54" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="54" subjects_affected="45" subjects_at_risk="476"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="131" subjects_affected="113" subjects_at_risk="476"/>
                <counts group_id="E2" events="66" subjects_affected="57" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="476"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="476"/>
                <counts group_id="E2" events="123" subjects_affected="119" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="142" subjects_affected="128" subjects_at_risk="476"/>
                <counts group_id="E2" events="286" subjects_affected="246" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="476"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="475"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="51" subjects_affected="46" subjects_at_risk="476"/>
                <counts group_id="E2" events="87" subjects_affected="76" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="253" subjects_affected="201" subjects_at_risk="476"/>
                <counts group_id="E2" events="166" subjects_affected="144" subjects_at_risk="475"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Services</name_or_title>
      <organization>Eisai, Inc.</organization>
      <phone>1-888-422-4743</phone>
      <email>esi_medinfo@eisai.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

